Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$48.30 USD
-0.68 (-1.39%)
Updated May 24, 2024 04:00 PM ET
After-Market: $48.28 -0.02 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Cytokinetics, Incorporated [CYTK]
Reports for Purchase
Showing records 221 - 240 ( 305 total )
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
KOLs See Clear Benefit; Balancing Act with Tolerability Now; Maintain Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Rays of Sunshine on Tirasemtiv and KOL Excitement; Maintain Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
ALS Wins; Patients and Our Call Lose; Omecamtiv Buffers; Target to $13
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Platform Presentation for BENEFIT-ALS Data; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
COSMIC-HF Expansion Presses Start; ALS Data Soon; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
''107 Moves Forward; $2 Million To the Bank; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Excitement Building for April Data; We''re In; Re-Initiating at Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Tirasemtiv Phase IIb Trial Design Finalized, Study to Initiate in 4Q12
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Tirasemtiv Phase IIb Trial Design Finalized, Study to Initiate in 4Q12
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M